Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
Journal of Labelled Compounds and Radiopharmaceuticals · 2024
DOI: 10.1002/jlcr.4121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Runze Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Delft, T…. Hauptthemen laut MEDLINE: Bismuth, Tellurium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Radionuclide therapy employing alpha emitters holds great potential for personalized cancer treatment. However, certain challenges remain when designing alpha radiopharmaceuticals, including the lack of stability of used radioconjugates due to nuclear decay events. In this work, ultrasmall silver telluride nanoparticles with a core diameter of 2.1 nm were prepared and radiolabeled with lead‐212 using a chelator‐free method with a radiolabeling efficiency of 75%. The results from the in vitro radiochemical stability assay indicated a very high retention of bismuth‐212 despite the internal conversion effects originating from the decay of 212 Pb. To further evaluate the potential of the nanoparticles, they were radiolabeled with indium‐111, and their cell uptake and subcellular distribution were determined in 2D U87 cells, showing accumulation in the nucleus. Although not intentional, it was observed that the indium‐111‐radiolabeled nanoparticles induced efficient tumor cell killing, which was attributed to the Auger electrons emitted by indium‐111. Combining the results obtained in this work with other favorable properties such as fast renal clearance and the possibility to attach targeting vectors on the surface of the nanoparticles, all well‐known from the literature, these ultra‐small silver telluride nanoparticles provide exciting opportunities for the design of theragnostic radiopharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Delft, The Netherlands.
ORCID-Profile: Runze Wang
Zitieren
APA
Wang, R., Wolterbeek, H. T., & Denkova, A. G. (2024). Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4121
Vancouver
Wang R, Wolterbeek HT, Denkova AG. Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4121
BibTeX
@article{Wang2024,
author = {Wang, Runze and Wolterbeek, Hubert Th and Denkova, Antonia G},
title = {Lead‐212/Bismuth‐212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2024},
doi = {10.1002/jlcr.4121}
}
EUVIMED